Vanda Pharmaceuticals (NASDAQ:VNDA) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research note issued on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Several other analysts also recently issued reports on VNDA. HC Wainwright began coverage on shares of Vanda Pharmaceuticals in a research report on Thursday, October 31st. They issued a “buy” rating and a $18.00 price target for the company. Cantor Fitzgerald lifted their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday, August 1st.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ:VNDA opened at $4.98 on Friday. The firm has a market cap of $290.38 million, a P/E ratio of -17.79 and a beta of 0.77. Vanda Pharmaceuticals has a 52-week low of $3.44 and a 52-week high of $6.75. The business’s 50 day simple moving average is $4.80 and its two-hundred day simple moving average is $5.27.

Insider Activity at Vanda Pharmaceuticals

In related news, Director Stephen Ray Mitchell sold 5,000 shares of the firm’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the transaction, the director now directly owns 44,857 shares of the company’s stock, valued at $231,910.69. This trade represents a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD boosted its stake in shares of Vanda Pharmaceuticals by 18.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 2,425 shares during the last quarter. Panagora Asset Management Inc. lifted its holdings in Vanda Pharmaceuticals by 4.3% during the second quarter. Panagora Asset Management Inc. now owns 60,434 shares of the biopharmaceutical company’s stock worth $341,000 after acquiring an additional 2,509 shares during the period. Verition Fund Management LLC boosted its position in Vanda Pharmaceuticals by 7.8% in the third quarter. Verition Fund Management LLC now owns 40,285 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 2,927 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in Vanda Pharmaceuticals by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock valued at $2,796,000 after purchasing an additional 3,473 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Vanda Pharmaceuticals by 64.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,211 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 4,374 shares during the last quarter. 88.14% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.